Compare Stocks: PROK, RXRX, BCAX, and NTLA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCAX Bicara Therapeutics	$23.90 -2.0%	$26.55	$10.30 ▼ $30.99	$1.58B	-0.75	675,586 shs	496,341 shs
NTLA Intellia Therapeutics	$12.84 +3.2%	$13.47	$7.95 ▼ $28.25	$1.80B	1.81	3.55 million shs	3.34 million shs
PROK ProKidney	$1.61 +13.4%	$1.67	$1.30 ▼ $3.48	$486.74M	1.66	1.14 million shs	1.72 million shs
RXRX Recursion Pharmaceuticals	$3.50 +4.8%	$3.30	$2.77 ▼ $7.18	$1.87B	1.03	15.98 million shs	22.85 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCAX Bicara Therapeutics	0.00%	-1.57%	-13.81%	+10.24%	+118.07%
NTLA Intellia Therapeutics	0.00%	+7.81%	+15.68%	+1.90%	+25.76%
PROK ProKidney	0.00%	+21.05%	+5.92%	-8.00%	-29.39%
RXRX Recursion Pharmaceuticals	0.00%	+10.76%	+16.28%	+16.28%	-26.62%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCAX Bicara Therapeutics	$23.90 -2.0%	$26.55	$10.30 ▼ $30.99	$1.58B	-0.75	675,586 shs	496,341 shs
NTLA Intellia Therapeutics	$12.84 +3.2%	$13.47	$7.95 ▼ $28.25	$1.80B	1.81	3.55 million shs	3.34 million shs
PROK ProKidney	$1.61 +13.4%	$1.67	$1.30 ▼ $3.48	$486.74M	1.66	1.14 million shs	1.72 million shs
RXRX Recursion Pharmaceuticals	$3.50 +4.8%	$3.30	$2.77 ▼ $7.18	$1.87B	1.03	15.98 million shs	22.85 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCAX Bicara Therapeutics	0.00%	-1.57%	-13.81%	+10.24%	+118.07%
NTLA Intellia Therapeutics	0.00%	+7.81%	+15.68%	+1.90%	+25.76%
PROK ProKidney	0.00%	+21.05%	+5.92%	-8.00%	-29.39%
RXRX Recursion Pharmaceuticals	0.00%	+10.76%	+16.28%	+16.28%	-26.62%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCAX Bicara Therapeutics	2.80	Moderate Buy	$32.64	36.55% Upside
NTLA Intellia Therapeutics	2.35	Hold	$21.15	64.74% Upside
PROK ProKidney	2.67	Moderate Buy	$12.00	645.34% Upside
RXRX Recursion Pharmaceuticals	2.20	Hold	$8.06	130.29% Upside

Current Analyst Ratings Breakdown

Latest PROK, RXRX, BCAX, and NTLA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	BCAX Bicara Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/18/2026	BCAX Bicara Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$35.00
8/18/2026	BCAX Bicara Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/17/2026	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$5.30
8/12/2026	BCAX Bicara Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$30.00 ➝ $33.00
8/12/2026	BCAX Bicara Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$18.00 ➝ $20.00
8/12/2026	BCAX Bicara Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$18.00 ➝ $20.00
8/12/2026	BCAX Bicara Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$16.00 ➝ $23.00
8/12/2026	BCAX Bicara Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$28.00 ➝ $39.00
8/11/2026	BCAX Bicara Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$37.00 ➝ $39.00
8/7/2026	NTLA Intellia Therapeutics	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Outperform	$24.00

(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	$7.08 per share	N/A
NTLA Intellia Therapeutics	$67.67M	26.59	N/A	N/A	$5.19 per share	2.47
PROK ProKidney	$890K	546.89	N/A	N/A	($2.92) per share	-0.55
RXRX Recursion Pharmaceuticals	$74.68M	25.09	N/A	N/A	$1.71 per share	2.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCAX Bicara Therapeutics	-$137.95M	-$3.10	N/A	N/A	N/A	N/A	-41.49%	-38.59%	11/9/2026 (Estimated)
NTLA Intellia Therapeutics	-$412.69M	-$3.36	N/A	N/A	N/A	-672.16%	-57.79%	-47.29%	11/5/2026 (Estimated)
PROK ProKidney	-$68.99M	-$0.55	N/A	N/A	N/A	-10,288.39%	N/A	-27.39%	11/9/2026 (Estimated)
RXRX Recursion Pharmaceuticals	-$644.76M	-$1.04	N/A	N/A	N/A	-945.94%	-50.41%	-38.25%	11/4/2026 (Estimated)

Latest PROK, RXRX, BCAX, and NTLA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	BCAX Bicara Therapeutics	-$0.8198	-$0.82	-$0.0002	-$0.82	N/A	N/A
8/10/2026	Q2 2026	PROK ProKidney	-$0.14	-$0.15	-$0.01	-$0.15	$0.19 million	$0.15 million
8/6/2026	Q2 2026	NTLA Intellia Therapeutics	-$0.7993	-$0.80	-$0.0007	-$0.80	$12.98 million	$7.66 million
8/5/2026	Q2 2026	RXRX Recursion Pharmaceuticals	-$0.24	-$0.25	-$0.01	-$0.25	$10.97 million	$7.67 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCAX Bicara Therapeutics	N/A	11.59	11.59
NTLA Intellia Therapeutics	N/A	6.65	6.65
PROK ProKidney	N/A	8.36	8.36
RXRX Recursion Pharmaceuticals	0.01	5.03	5.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCAX Bicara Therapeutics	N/A
NTLA Intellia Therapeutics	88.77%
PROK ProKidney	51.59%
RXRX Recursion Pharmaceuticals	89.06%

Insider Ownership

Company	Insider Ownership
BCAX Bicara Therapeutics	13.80%
NTLA Intellia Therapeutics	3.50%
PROK ProKidney	39.83%
RXRX Recursion Pharmaceuticals	6.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCAX Bicara Therapeutics	32	66.17 million	57.04 million	N/A
NTLA Intellia Therapeutics	600	140.13 million	135.22 million	Optionable
PROK ProKidney	3	302.32 million	181.91 million	Optionable
RXRX Recursion Pharmaceuticals	400	535.34 million	499.74 million	Optionable

PROK, RXRX, BCAX, and NTLA Headlines

Recent News About These Companies

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 9.8% - Still a Buy?

August 19, 2026 | marketbeat.com

The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci

August 18, 2026 | finance.yahoo.com

Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says

August 17, 2026 | finance.yahoo.com

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma

August 17, 2026 | zacks.com

Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates

August 17, 2026 | marketbeat.com

Recursion (RXRX) Q2 2026 Earnings Call Transcript

August 12, 2026 | fool.com

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcript

August 11, 2026 | seekingalpha.com

Stock Traders Purchase High Volume of Put Options on Recursion Pharmaceuticals (NASDAQ:RXRX)

August 11, 2026 | marketbeat.com

The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)

August 11, 2026 | 247wallst.com

Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News

August 10, 2026 | seekingalpha.com

TD Cowen Keeps Their Hold Rating on Recursion Pharmaceuticals (RXRX)

August 9, 2026 | theglobeandmail.com

Recursion Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 9, 2026 | seekingalpha.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Cut to "Strong Sell" at Wall Street Zen

August 8, 2026 | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Director Blake Borgeson Sells 30,000 Shares of Stock

August 7, 2026 | insidertrades.com

Blake Borgeson Sells 30,000 Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) Stock

August 6, 2026 | marketbeat.com

RXRX Q2 Earnings Miss Estimates, Revenues Fall Y/Y, Stock Down

August 6, 2026 | zacks.com

Recursion Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary

August 6, 2026 | app.moby.coA

Bank of New York Mellon Corp Boosts Stake in Recursion Pharmaceuticals, Inc. $RXRX

August 6, 2026 | marketbeat.com

Recursion outlines $375M 2026 cash OpEx guidance while advancing first Genentech neuroscience target

August 5, 2026 | seekingalpha.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Releases Earnings Results, Misses Estimates By $0.01 EPS

August 5, 2026 | marketbeat.com

Recursion Pharmaceuticals Q2 Earnings Call Highlights

August 5, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROK, RXRX, BCAX, and NTLA Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

$23.90 -0.49 (-2.01%)

As of 08/21/2026 04:00 PM Eastern

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Intellia Therapeutics NASDAQ:NTLA

$12.84 +0.40 (+3.22%)

As of 08/21/2026 04:00 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

ProKidney NASDAQ:PROK

$1.61 +0.19 (+13.38%)

As of 08/21/2026 04:00 PM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Recursion Pharmaceuticals NASDAQ:RXRX

$3.50 +0.16 (+4.79%)

As of 08/21/2026 04:00 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PROK, RXRX, BCAX, and NTLA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PROK, RXRX, BCAX, and NTLA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PROK, RXRX, BCAX, and NTLA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROK, RXRX, BCAX, and NTLA Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

Intellia Therapeutics NASDAQ:NTLA

ProKidney NASDAQ:PROK

Recursion Pharmaceuticals NASDAQ:RXRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PROK, RXRX, BCAX, and NTLA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PROK, RXRX, BCAX, and NTLA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PROK, RXRX, BCAX, and NTLA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROK, RXRX, BCAX, and NTLA Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

Intellia Therapeutics NASDAQ:NTLA

ProKidney NASDAQ:PROK

Recursion Pharmaceuticals NASDAQ:RXRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools